Logan Coy Related postsA Phase 2/3, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancerSeptember 11, 2026A Phase 2, Open-Label Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast CancerSeptember 10, 2026A Phase 1/2 Open-Label, Dose-Escalation Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Advanced, EGFR-Mutant, Metastatic NSCLC that Progressed after OsimertinibSeptember 11, 2026 Previous postA Phase 1 Study of IM-1021 in Participants with Advanced MalignanciesNext postA Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation Study of Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell Lung Cancer